Shenzhen Beimei Pharmaceutical Co., Ltd. is an enterprise specializing in the development, introduction and sales of pediatric medicines. Product development strategies include independent research and development and the introduction of excellent foreign pediatric products. The company focuses on pediatric chemical prescription medicines and with an efficient BD team to solve the problem of domestic pediatric medicine accessibility and compliance. It conducts project research and introduction in combination with clinical and market conditions. The approved products and services are competitive to meet the domestic clinical urgent and unmet medical needs, have broad market prospects. Through entrusted R&D, import product license, independent R&D and other models, we have successively developed more than ten generic products projects, forming a strong pediatric chemical prescription medicine development capability.
In order to focus on building its own pediatric R&D platform, Beimei Pharma established the R&D Center in Shenzhen Yifenghua Industrial Park in April 2020, and established Beimei Research and Development (Shenzhen) Co., Ltd. in August 2022. In April 2023, it relocated to the International Biomedical Industry Park in Futian Free Trade Zone.
The company's R&D team is growing day by day, with nearly 100 R&D personnel including PhDs, masters, overseas returnee talents, and core technical talents, accounting for more than half of the total number of employees in the company, providing strong talent support for the high-quality development of the company. At the same time, we have also established in-depth and extensive scientific research project cooperation and exchanges with China Pharmaceutical University and multiple professional drug research and development institutions home and abroad. Aiming at the pain points of children's clinical medication, three technical platforms of pediatric slow and controlled release, oral instant film and transdermal gel with independent intellectual property rights have been set up. At the same time, from the perspective of improving children's drug compliance, we will develop new flavor masking technologies, mixed granulation and other prescription process technologies with independent intellectual property rights, forming a strong R&D capability for high-end formulations of pediatric prescription medicines.
Our company has established good cooperative relations with scientific research institutions such as China Pharmaceutical University, Guangzhou Renheng Pharmaceutical Technology Co., Ltd. and other R&D CRO companies. We cooperate in prescription development and quality research, such as BM_R03_TM and other pediatric medicines.
At the same time, our company has established good cooperative relations with several drug manufacturing enterprises in Shandong, Sichuan, Guangdong and other places. Our company has launched the entrusted production cooperation of products in research under the framework of the MAH (Marketing Authorization Holder) system. And has planned quality assurance and pharmacovigilance system covering the entire life cycle of the medicine, fulfill the main responsibility of the MAH.